Synthon preference in a hydrated β‐resorcylic acid structure and its cocrystal with thymine

Multicomponent crystals or cocrystals play a significant role in crystal engineering, the main objective of which is to understand the role of intermolecular interactions and to utilize such understanding in the design of novel crystal structures. Molecules possessing carboxylic acid and amide functional groups are good candidates for forming cocrystals. β‐Resorcylic acid monohydrate, C₇H₆O₄·H₂O, (I), crystallizes in the triclinic space group P with one β‐resorcylic acid molecule and one water molecule in the asymmetric unit. The cocrystal thymine–β‐resorcylic acid–water (1/1/1), C₅H₆N₂O₂·C₇H₆O₄·H₂O, (II), crystallizes in the orthorhombic space group Pca2₁, with one molecule each of thymine, β‐resorcylic acid and water in the asymmetric unit. All available donor and acceptor atoms in (I) and (II) are utilized for hydrogen bonding. The acid and amide functional groups are well known for the formation of self‐complementary acid–acid and amide–amide homosynthons. In (I), an acid–acid homosynthon is observed, while in (II), an amide–acid heterosynthon is present. In (I), the β‐resorcylic acid molecule exhibits the expected intramolecular S(6) motif between the hydroxy and carbonyl O atoms, and an intermolecular R₂²(8) dimer motif between the carboxylic acid groups; only the former motif is observed in (II). The water solvent molecule in (I) propagates the discrete dimers into two‐dimensional hydrogen‐bonded sheets. In (II), thymine and β‐resorcylic acid molecules do not form self‐complementary amide–amide and acid–acid homosynthons; instead, a thymine–β‐resorcylic acid heterosynthon is observed. With the help of the water molecule, this heterosynthon is aggregated into a three‐dimensional hydrogen‐bonded network. The absence of thymine base pairing in (II) might be linked to the availability of additional functional groups and the preference of the donor and acceptor hydrogen‐bond combinations.     

The cocrystal nicotinamide–succinic acid (2/1)

In the asymmetric unit of the crystal structure of nicotinamide–succinic acid (2/1), 2C₆H₆N₂O·C₄H₆O₄, there are two independent nicotinamide molecules in general positions and two half succinic acid molecules which lie about inversion centres. The structure contains acid–pyridine and amide–amide synthons with nicotinamide molecules forming ladders of alternating R₂²(8) and R₄²(8) rings linked through succinic acid to generate a corrugated hydrogen‐bonded sheet. This sheet is a common supramolecular unit found in other 2:1 nicotinamide–dicarboxylic acid cocrystals, but the presence of two crystallographically distinct nicotinamides with anti and syn conformations, forming two distinct sheets within the same structure, is a novel packing feature in this type of material.     

2,6‐Bis(1‐benzyl‐1H‐1,2,3‐triazol‐4‐yl)pyridine and its octahedral copper complex

In the tridentate ligand 2,6‐bis(1‐benzyl‐1H‐1,2,3‐triazol‐4‐yl)pyridine, C₂₃H₁₉N₇, both sets of triazole N atoms are anti with respect to the pyridine N atom, while in the copper complex aqua[2,6‐bis(1‐benzyl‐1H‐1,2,3‐triazol‐4‐yl)pyridine](pyridine)(tetrafluoroborato)copper(II) tetrafluoroborate, [Cu(BF₄)(C₅H₅N)(C₂₃H₁₉N₇)(H₂O)]BF₄, the triazole N atoms are in the syn–syn conformation. The coordination of the Cu^II atom is distorted octahedral. The ligand structure is stabilized through intermolecular C—H...N interactions, while the crystal structure of the Cu complex is stabilized through water‐ and BF₄‐mediated hydrogen bonds. Photoluminiscence studies of the ligand and complex show that the ligand is fluorescent due to triazole–pyridine conjugation, but that the fluorescence is quenched on complexation.     

Supramolecular hydrogen‐bonding patterns in two cocrystals of the N(7)–H tautomeric form of N6‐benzoyladenine: N6‐benzoyladenine–3‐hydroxypyridinium‐2‐carboxylate (1/1) and N6‐benzoyladenine–DL‐tartaric acid (1/1)

Two novel cocrystals of the N(7)—H tautomeric form of N⁶‐benzoyladenine (BA), namely N⁶‐benzoyladenine–3‐hydroxypyridinium‐2‐carboxylate (3HPA) (1/1), C₁₂H₉N₅O·C₆H₅NO₃, (I), and N⁶‐benzoyladenine–DL‐tartaric acid (TA) (1/1), C₁₂H₉N₅O·C₄H₆O₆, (II), are reported. In both cocrystals, the N⁶‐benzoyladenine molecule exists as the N(7)—H tautomer, and this tautomeric form is stabilized by intramolecular N—H...O hydrogen bonding between the benzoyl C=O group and the N(7)—H hydrogen on the Hoogsteen site of the purine ring, forming an S(7) motif. The dihedral angle between the adenine and phenyl planes is 0.94 (8)° in (I) and 9.77 (8)° in (II). In (I), the Watson–Crick face of BA (N6—H and N1; purine numbering) interacts with the carboxylate and phenol groups of 3HPA through N—H...O and O—H...N hydrogen bonds, generating a ring‐motif heterosynthon [graph set R₂²(6)]. However, in (II), the Hoogsteen face of BA (benzoyl O atom and N7; purine numbering) interacts with TA (hydroxy and carbonyl O atoms) through N—H...O and O—H...O hydrogen bonds, generating a different heterosynthon [graph set R₂²(4)]. Both crystal structures are further stabilized by π–π stacking interactions.     

Hydrogen‐bonding interactions in the 4‐aminobenzoic acid salt of atenolol monohydrate

Atenolol {or 4‐[2‐hydroxy‐3‐(isopropylamino)propoxy]phenylacetamide} crystallizes with 4‐aminobenzoic acid to give the salt {3‐[4‐(aminocarbonylmethyl)phenoxy]‐2‐hydroxypropyl}isopropylammonium 4‐aminobenzoate monohydrate, C₁₄H₂₃N₂O₃⁺·C₇H₆NO₂⁻·H₂O. In the crystal structure, the water molecule, the carboxylate group of 4‐aminobenzoate, and the hydroxy and ether O atoms of atenolol form a supramolecular R₃³(11) heterosynthon. Three other types of supramolecular synthons link the asymmetric unit into a two‐dimensional structure.     

The cocrystal of 3‐hydroxy‐2‐naphthoic acid and 4,4′‐bipyridine

4,4′‐Bipyridine cocrystallizes with 3‐hydroxy‐2‐naphthoic acid in a 1:2 ratio to give a centrosymmetric three‐component supra­molecular adduct, namely 3‐hydroxy‐2‐naphthoic acid–4,4′‐bipyridine (2/1), C₁₁H₈O₃·0.5C₁₀H₈N₂, in which 4,4′‐bipyridine is located on an inversion center. The pyridine–carboxylic acid heterosynthon generates an infinite one‐dimensional hydrogen‐bonded chain viaπ–π inter­actions between naphthyl and 4,4′‐bipyridine groups. The one‐dimensional chains are further assembled into a three‐dimensional network by weak C—H⋯π inter­actions between pyridyl and naphthyl rings, and C—H⋯O inter­actions between 3‐hydroxy‐2‐naphthoic acid mol­ecules.     

Cocrystals of the antimalarial drug 11‐azaartemisinin with three alkenoic acids of 1:1 or 2:1 stoichiometry

The stoichiometry, X‐ray structures and stability of four pharmaceutical cocrystals previously identified from liquid‐assisted grinding (LAG) of 11‐azaartemisinin (11‐Aza; systematic name: 1,5,9‐trimethyl‐14,15,16‐trioxa‐11‐azatetracyclo[10.3.1.0^4,13.0^8,13]hexadecan‐10‐one) with trans‐cinnamic (Cin), maleic (Mal) and fumaric (Fum) acids are herein reported. trans‐Cinnamic acid, a mono acid, forms 1:1 cocrystal 11‐Aza:Cin ( 1 , C₁₅H₂₃NO₄·C₉H₈O₂). Maleic acid forms both 1:1 cocrystal 11‐Aza:Mal ( 2 , C₁₅H₂₃NO₄·C₄H₄O₄), in which one COOH group is involved in self‐catenation, and 2:1 cocrystal 11‐Aza₂:Mal ( 3 , 2C₁₅H₂₃NO₄·C₄H₄O₄). Its isomer, fumaric acid, only affords 2:1 cocrystal 11‐Aza₂:Fum ( 4 ). All cocrystal formation appears driven by acid–lactam R₂²(8) heterosynthons with short O—H…O=C hydrogen bonds [O…O = 2.56 (2) Å], augmented by weaker C=O…H—N contacts. Despite a better packing efficiency, cocrystal 3 is metastable with respect to 2 , probably due to a higher conformational energy for the maleic acid molecule in its structure. In each case, the microcrystalline powders from LAG were useful in providing seeding for the single‐crystal growth.     

Supramolecular architectures in the salt trimethoprimium ferrocene‐1‐carboxylate and the cocrystal 4‐amino‐5‐chloro‐2,6‐dimethylpyrimidine–ferrocene‐1‐carboxylic acid (1/1)

In the salt trimethoprimium ferrocenecarboxylate [systematic name: 2,4‐diamino‐5‐(3,4,5‐trimethoxybenzyl)pyrimidin‐1‐ium ferrocene‐1‐carboxylate], (C₁₄H₁₉N₄O₃)[Fe(C₅H₅)(C₆H₄O₂)], (I), of the antibacterial compound trimethoprim, the carboxylate group interacts with the protonated aminopyrimidine group of trimethoprim via two N—H…O hydrogen bonds, generating a robust R ₂²(8) ring motif (heterosynthon). However, in the cocrystal 4‐amino‐5‐chloro‐2,6‐dimethylpyrimidine–ferrocene‐1‐carboxylic acid (1/1), [Fe(C₅H₅)(C₆H₅O₂)]·C₆H₈ClN₃, (II), the carboxyl–aminopyrimidine interaction [R ₂²(8) motif] is absent. The carboxyl group interacts with the pyrimidine ring via a single O—H…N hydrogen bond. The pyrimidine rings, however, form base pairs via a pair of N—H…N hydrogen bonds, generating an R ₂²(8) supramolecular homosynthon. In salt (I), the unsubstituted cyclopentadienyl ring is disordered over two positions, with a refined site‐occupation ratio of 0.573 (10):0.427 (10). In this study, the two five‐membered cyclopentadienyl (Cp) rings of ferrocene are in a staggered conformation, as is evident from the C…Cg …Cg …C pseudo‐torsion angles, which are in the range 36.13–37.53° for (I) and 22.58–23.46° for (II). Regarding the Cp ring of the minor component in salt (I), the geometry of the ferrocene ring is in an eclipsed conformation, as is evident from the C…Cg …Cg …C pseudo‐torsion angles, which are in the range 79.26–80.94°. Both crystal structures are further stabilized by weak π–π interactions.     

Three 2‐(methysulfanyl)nicotinamides

The molecular conformations of three N‐alkyl‐2‐(methylsulfanyl)nicotinamide derivatives, namely N‐cyclohexyl‐2‐(methylsulfanyl)nicotinamide, C₁₃H₁₈N₂OS, (I), N‐isopropyl‐2‐(methylsulfanyl)nicotinamide, C₁₀H₁₄N₂OS, (II), in which there are two molecules in the asymmetric unit which were chosen to form a hydrogen‐bonded pair, and N‐(2‐hydroxyethyl)‐2‐(methylsulfanyl)nicotinamide dihydrate, C₉H₁₂N₂O₂S·2H₂O, (III), are compared with those of four unsubstituted N‐alkylnicotinamide compounds. The substituted compounds show a higher degree of torsion of the pyridine ring with respect to the amide group than do the unsubstituted compounds, with dihedral angles in the range 40–60° for the former and 20–35° for the latter. In (I) and (II), the supramolecular structure is defined by amide‐N to carbonyl‐O chains. In (III), the nicotinamide molecules are linked by hydrogen bonds to two water molecules resulting in two linked chains of rings which form the three‐dimensional network.     

Supramolecular hydrogen‐bonding patterns in salts of the antifolate drugs trimethoprim and pyrimethamine

Nine salts of the antifolate drugs trimethoprim and pyrimethamine, namely, trimethoprimium [or 2,4‐diamino‐5‐(3,4,5‐trimethoxybenzyl)pyrimidin‐1‐ium] 2,5‐dichlorothiophene‐3‐carboxylate monohydrate (TMPDCTPC, 1:1), C₁₄H₁₉N₄O₃⁺·C₅HCl₂O₂S⁻, ( I ), trimethoprimium 3‐bromothiophene‐2‐carboxylate monohydrate, (TMPBTPC, 1:1:1), C₁₄H₁₉N₄O₃⁺·C₅H₂BrO₂S⁻·H₂O, ( II ), trimethoprimium 3‐chlorothiophene‐2‐carboxylate monohydrate (TMPCTPC, 1:1:1), C₁₄H₁₉N₄O₃⁺·C₅H₂ClO₂S⁻·H₂O, ( III ), trimethoprimium 5‐methylthiophene‐2‐carboxylate monohydrate (TMPMTPC, 1:1:1), C₁₄H₁₉N₄O₃⁺·C₆H₅O₂S⁻·H₂O, ( IV ), trimethoprimium anthracene‐9‐carboxylate sesquihydrate (TMPAC, 2:2:3), C₁₄H₁₉N₄O₃⁺·C₁₅H₉O₂⁻·1.5H₂O, ( V ), pyrimethaminium [or 2,4‐diamino‐5‐(4‐chlorophenyl)‐6‐ethylpyrimidin‐1‐ium] 2,5‐dichlorothiophene‐3‐carboxylate (PMNDCTPC, 1:1), C₁₂H₁₄ClN₄⁺·C₅HCl₂O₂S⁻, ( VI ), pyrimethaminium 5‐bromothiophene‐2‐carboxylate (PMNBTPC, 1:1), C₁₂H₁₄ClN₄⁺·C₅H₂BrO₂S⁻, ( VII ), pyrimethaminium anthracene‐9‐carboxylate ethanol monosolvate monohydrate (PMNAC, 1:1:1:1), C₁₂H₁₄ClN₄⁺·C₁₅H₉O₂⁻·C₂H₅OH·H₂O, ( VIII ), and bis(pyrimethaminium) naphthalene‐1,5‐disulfonate (PMNNSA, 2:1), 2C₁₂H₁₄ClN₄⁺·C₁₀H₆O₆S₂²⁻, ( IX ), have been prepared and characterized by single‐crystal X‐ray diffraction. In all the crystal structures, the pyrimidine N1 atom is protonated. In salts ( I )–( III ) and ( VI )–( IX ), the 2‐aminopyrimidinium cation interacts with the corresponding anion via a pair of N—H…O hydrogen bonds, generating the robust R₂²(8) supramolecular heterosynthon. In salt ( IV ), instead of forming the R₂²(8) heterosynthon, the carboxylate group bridges two pyrimidinium cations via N—H…O hydrogen bonds. In salt ( V ), one of the carboxylate O atoms bridges the N1—H group and a 2‐amino H atom of the pyrimidinium cation to form a smaller R₂¹(6) ring instead of the R₂²(8) ring. In salt ( IX ), the sulfonate O atoms mimic the role of carboxylate O atoms in forming an R₂²(8) ring motif. In salts ( II )–( IX ), the pyrimidinium cation forms base pairs via a pair of N—H…N hydrogen bonds, generating a ring motif [R₂²(8) homosynthon]. Compounds ( II ) and ( III ) are isomorphous. The quadruple DDAA (D = hydrogen‐bond donor and A = hydrogen‐bond acceptor) array is observed in ( I ). In salts ( II )–( IV ) and ( VI )–( IX ), quadruple DADA arrays are present. In salts ( VI ) and ( VII ), both DADA and DDAA arrays co‐exist. The crystal structures are further stabilized by π–π stacking interactions [in ( I ), ( V ) and ( VII )–( IX )], C—H…π interactions [in ( IV )–( V ) and ( VII )–( IX )], C—Br…π interactions [in ( II )] and C—Cl…π interactions [in ( I ), ( III ) and ( VI )]. Cl…O and Cl…Cl halogen‐bond interactions are present in ( I ) and ( VI ), with distances and angles of 3.0020 (18) and 3.5159 (16) Å, and 165.56 (10) and 154.81 (11)°, respectively.     

Supramolecular architectures in cytosinium 6‐chloronicotinate monohydrate and 5‐bromo‐6‐methylisocytosinium hydrogen sulfate

Aminopyrimidine derivatives are biologically important as they are components of nucleic acids and drugs. The crystals of two new salts, namely cytosinium 6‐chloronicotinate monohydrate, C₄H₆N₃O⁺·C₆H₃ClNO₂⁻·H₂O, ( I ), and 5‐bromo‐6‐methylisocytosinium hydrogen sulfate (or 2‐amino‐5‐bromo‐4‐oxo‐6‐methylpyrimidinium hydrogen sulfate), C₅H₇BrN₃O⁺·HSO₄⁻, ( II ), have been prepared and characterized by single‐crystal X‐ray diffraction. The pyrimidine ring of both compounds is protonated at the imine N atom. In hydrated salt ( I ), the primary R₂²(8) ring motif (supramolecular heterosynthon) is formed via a pair of N—H…O(carboxylate) hydrogen bonds. The cations, anions and water molecule are hydrogen bonded through N—H…O, N—H…N, O—H…O and C—H…O hydrogen bonds, forming R₂²(8), R₃²(7) and R₅⁵(21) motifs, leading to a hydrogen‐bonded supramolecular sheet structure. The supramolecular double sheet structure is formed via water–carboxylate O—H…O hydrogen bonds and π–π interactions between the anions and the cations. In salt ( II ), the hydrogen sulfate ions are linked via O—H…O hydrogen bonds to generate zigzag chains. The aminopyrimidinium cations are embedded between these zigzag chains. Each hydrogen sulfate ion bridges two cations via pairs of N—H…O hydrogen bonds and vice versa, generating two R₂²(8) ring motifs (supramolecular heterosynthon). The cations also interact with one another via halogen–halogen (Br…Br) and halogen–oxygen (Br…O) interactions.     

Supramolecular architectures in two 1:1 cocrystals of 5‐fluorouracil with 5‐bromothiophene‐2‐carboxylic acid and thiophene‐2‐carboxylic acid

In solid‐state engineering, cocrystallization is a strategy actively pursued for pharmaceuticals. Two 1:1 cocrystals of 5‐fluorouracil (5FU; systematic name: 5‐fluoro‐1,3‐dihydropyrimidine‐2,4‐dione), namely 5‐fluorouracil–5‐bromothiophene‐2‐carboxylic acid (1/1), C₅H₃BrO₂S·C₄H₃FN₂O₂, (I), and 5‐fluorouracil–thiophene‐2‐carboxylic acid (1/1), C₄H₃FN₂O₂·C₅H₄O₂S, (II), have been synthesized and characterized by single‐crystal X‐ray diffraction studies. In both cocrystals, carboxylic acid molecules are linked through an acid–acid R ₂²(8) homosynthon (O—H…O) to form a carboxylic acid dimer and 5FU molecules are connected through two types of base pairs [homosynthon, R ₂²(8) motif] via a pair of N—H…O hydrogen bonds. The crystal structures are further stabilized by C—H…O interactions in (II) and C—Br…O interactions in (I). In both crystal structures, π–π stacking and C—F…π interactions are also observed.     

Adsorption behaviour of a CdII–triazole MOF for butan‐2‐one in a single‐crystal‐to‐single‐crystal (SCSC) fashion: the role of hydrogen bonding and C—H…π interactions

The adsorption behaviour of the Cd^II–MOF {[Cd(L)₂(ClO₄)₂]·H₂O ( 1 ), where L is 4‐amino‐3,5‐bis[3‐(pyridin‐4‐yl)phenyl]‐1,2,4‐triazole, for butan‐2‐one was investigated in a single‐crystal‐to‐single‐crystal (SCSC) fashion. A new host–guest system that encapsulated butan‐2‐one molecules, namely poly[[bis{μ₃‐4‐amino‐3,5‐bis[3‐(pyridin‐4‐yl)phenyl]‐1,2,4‐triazole}cadmium(II)] bis(perchlorate) butanone sesquisolvate], {[Cd(C₂₄H₁₈N₆)₂](ClO₄)₂·1.5C₄H₈O}_n, denoted C₄H₈O@Cd‐MOF ( 2 ), was obtained via an SCSC transformation. MOF 2 crystallizes in the tetragonal space group P4₃2₁2. The specific binding sites for butan‐2‐one in the host were determined by single‐crystal X‐ray diffraction studies. N—H…O and C—H…O hydrogen‐bonding interactions and C—H…π interactions between the framework, ClO₄^? anions and guest molecules co‐operatively bind 1.5 butan‐2‐one molecules within the channels. The adsorption behaviour was further evidenced by ¹H NMR, IR, TGA and powder X‐ray diffraction experiments, which are consistent with the single‐crystal X‐ray analysis. A ¹H NMR experiment demonstrates that the supramolecular interactions between the framework, ClO₄^? anions and guest molecules in MOF 2 lead to a high butan‐2‐one uptake in the channel.     

Cinnamic acid hydrogen bonds to isoniazid and N′‐(propan‐2‐ylidene)isonicotinohydrazide,an in situ reaction product of isoniazid and acetone

A new polymorph of the cinnamic acid–isoniazid cocrystal has been prepared by slow evaporation, namely cinnamic acid–pyridine‐4‐carbohydrazide (1/1), C₉H₈O₂·C₆H₇N₃O. The crystal structure is characterized by a hydrogen‐bonded tetrameric arrangement of two molecules of isoniazid and two of cinnamic acid. Possible modification of the hydrogen bonding was investigated by changing the hydrazide group of isoniazid via an in situ reaction with acetone and cocrystallization with cinnamic acid. In the structure of cinnamic acid–N′‐(propan‐2‐ylidene)isonicotinohydrazide (1/1), C₉H₈O₂·C₉H₁₁N₃O, carboxylic acid–pyridine O—H...N and hydrazide–hydrazide N—H...O hydrogen bonds are formed.     

The hydrogen‐bonding patterns of 3‐phenylpropylammonium benzoate and 3‐phenylpropylammonium 3‐iodobenzoate: generation of chiral crystals from achiral molecules

The crystal structures and hydrogen‐bonding patterns of 3‐phenylpropylammonium benzoate, C₉H₁₄N⁺·C₇H₅O₂⁻, (I), and 3‐phenylpropylammonium 3‐iodobenzoate, C₉H₁₄N⁺·C₇H₄IO₂⁻, (II), are reported and compared. The addition of the I atom on the anion in (II) produces a different hydrogen‐bonding pattern to that of (I). In addition, the supramolecular heterosynthon of (II) produces a chiral crystal packing not observed in (I). Compound (I) packs in a centrosymmetric fashion and forms achiral one‐dimensional hydrogen‐bonded columns through charge‐assisted N—H...O hydrogen bonds. Compound (II) packs in a chiral space group and forms helical one‐dimensional hydrogen‐bonded columns with 2₁ symmetry, consisting of repeating R₄³(10) hydrogen‐bonded rings that are commonly observed in ammonium carboxylate salts containing chiral molecules. This hydrogen‐bond pattern, which has been observed repeatedly in ammonium carboxylate salts, thus provides a means of producing chiral crystal structures from achiral molecules.     

One barbiturate and two solvated thiobarbiturates containing the triply hydrogen‐bonded ADA/DAD synthon,plus one ansolvate and three solvates of their coformer 2,4‐diaminopyrimidine

A path to new synthons for application in crystal engineering is the replacement of a strong hydrogen‐bond acceptor, like a C=O group, with a weaker acceptor, like a C=S group, in doubly or triply hydrogen‐bonded synthons. For instance, if the C=O group at the 2‐position of barbituric acid is changed into a C=S group, 2‐thiobarbituric acid is obtained. Each of the compounds comprises two ADA hydrogen‐bonding sites (D = donor and A = acceptor). We report the results of cocrystallization experiments of barbituric acid and 2‐thiobarbituric acid, respectively, with 2,4‐diaminopyrimidine, which contains a complementary DAD hydrogen‐bonding site and is therefore capable of forming an ADA/DAD synthon with barbituric acid and 2‐thiobarbituric acid. In addition, pure 2,4‐diaminopyrimidine was crystallized in order to study its preferred hydrogen‐bonding motifs. The experiments yielded one ansolvate of 2,4‐diaminopyrimidine (pyrimidine‐2,4‐diamine, DAPY), C₄H₆N₄, (I), three solvates of DAPY, namely 2,4‐diaminopyrimidine–1,4‐dioxane (2/1), 2C₄H₆N₄·C₄H₈O₂, (II), 2,4‐diaminopyrimidine–N,N‐dimethylacetamide (1/1), C₄H₆N₄·C₄H₉NO, (III), and 2,4‐diaminopyrimidine–1‐methylpyrrolidin‐2‐one (1/1), C₄H₆N₄·C₅H₉NO, (IV), one salt of barbituric acid, viz. 2,4‐diaminopyrimidinium barbiturate (barbiturate is 2,4,6‐trioxopyrimidin‐5‐ide), C₄H₇N₄⁺·C₄H₃N₂O₃⁻, (V), and two solvated salts of 2‐thiobarbituric acid, viz. 2,4‐diaminopyrimidinium 2‐thiobarbiturate–N,N‐dimethylformamide (1/2) (2‐thiobarbiturate is 4,6‐dioxo‐2‐sulfanylidenepyrimidin‐5‐ide), C₄H₇N₄⁺·C₄H₃N₂O₂S⁻·2C₃H₇NO, (VI), and 2,4‐diaminopyrimidinium 2‐thiobarbiturate–N,N‐dimethylacetamide (1/2), C₄H₇N₄⁺·C₄H₃N₂O₂S⁻·2C₄H₉NO, (VII). The ADA/DAD synthon was succesfully formed in the salt of barbituric acid, i.e. (V), as well as in the salts of 2‐thiobarbituric acid, i.e. (VI) and (VII). In the crystal structures of 2,4‐diaminopyrimidine, i.e. (I)–(IV), R₂²(8) N—H…N hydrogen‐bond motifs are preferred and, in two structures, additional R₃²(8) patterns were observed.     

Two ZnII coordination complexes assembled by trithiocyanuric acid and two different N‐donor auxiliary ligands

The dipyridyl‐type building blocks 4‐amino‐3,5‐bis(pyridin‐3‐yl)‐1,2,4‐triazole (3‐bpt) and 4,4′‐bipyridine (bpy) have been used to assemble with Zn^II in the presence of trithiocyanuric acid (ttcH₃) to afford two coordination compounds, namely bis[4‐amino‐3,5‐bis(pyridin‐3‐yl)‐1,2,4‐triazole‐κN³]bis(trithiocyanurato‐κ²N,S)zinc(II), [Zn(C₃H₂N₃S₃)₂(C₁₂H₁₀N₆)₂]·2H₂O, (1), and catena‐poly[[[bis(trithiocyanurato‐κ²N,S)zinc(II)]‐μ‐4,4′‐bipyridine‐κ²N:N′] 4,4′‐bipyridine monosolvate], {[Zn₂(C₃H₂N₃S₃)₄(C₁₀H₈N₂)₃]·C₁₀H₈N₂}_n, (2). Single‐crystal X‐ray analysis indicates that complex (1) is a mononuclear structure, while complex (2) presents a one‐dimensional chain coordination motif. In both complexes, the central Zn^II cation adopts an octahedral geometry, coordinated by four N‐ and two S‐donor atoms. Notably, trithiocyanurate (ttcH₂⁻) adopts the same bidentate chelating coordination mode in each complex and exists in the thione tautomeric form. The 3‐bpt co‐ligand in (1) adopts a monodentate coordination mode and serves as a terminal pendant ligand, whereas the 4,4′‐bipyridine (bpy) ligand in (2) adopts a bidentate–bridging coordination mode. The different coordination characters of the different N‐donor auxiliary ligands lead to structural diversity for complexes (1) and (2). Further analysis indicates that the resultant three‐dimensional supramolecular networks for (1) and (2) arise through intermolecular N—H...S and N—H...N hydrogen bonds. Both complexes have been further characterized by FT–IR spectroscopy and elemental analyses.     

Crystal structure of pharmaceutical cocrystals of 2,6‐diaminopyridine with piracetam and theophylline

Pharmaceutical cocrystals are crystalline solids formed by an active pharmaceutical ingredient and a cocrystal former. The cocrystals 2,6‐diaminopyridine (DAP)–piracetam [PIR; systematic name: 2‐(2‐oxopyrrolidin‐1‐yl)acetamide] (1/1), C₅H₇N₃·C₆H₁₀N₂O₂, (I), and 2,6‐diaminopyridine–theophylline (TEO; systematic name: 1,3‐dimethyl‐7H‐purine‐2,6‐dione) (1/1), C₅H₇N₃·C₇H₈N₄O₂, (II), were prepared by the solvent‐assisted grinding method and were characterized by IR spectroscopy and powder X‐ray diffraction. Cocrystal (I) crystallized in the orthorhombic space group Pbca and showed a 1:1 stoichiometry. The DAP and PIR molecules are linked by an N—H…O hydrogen‐bond interaction. Self‐assembly of PIR molecules forms a sheet of C (4) and C (7) chains. Cocrystal (II) crystallized in the monoclinic P 2₁/c space group and also showed a 1:1 stoichiometry. The DAP and TEO molecules are connected by N—H…N and N—H…O hydrogen bonds, forming an R ₂²(9) heterosynthon. A bidimensional supramolecular array is formed by interlinked DAP–TEO tetramers, producing a two‐dimensional sheet.     

A 1:1 cocrystal of baicalein with nicotinamide

Cocrystallization of baicalein with nicotinamide yields a 1:1 cocrystal [systematic name: pyridine‐3‐carboxamide–5,6,7‐trihydroxy‐2‐phenyl‐4H‐chromen‐4‐one (1/1)], C₆H₆N₂O·C₁₅H₁₀O₅. The asymmetric unit contains one baicalein and one nicotinamide molecule, both in neutral forms. Molecules in the cocrystal form column motifs stabilized by an array of intermolecular hydrogen bonds.     

Pharmaceutical salts of emoxypine with dicarboxylic acids

New salt forms of the antioxidant drug emoxypine (EMX, 2‐ethyl‐6‐methylpyridin‐3‐ol) with pharmaceutically acceptable maleic (Mlt), malonic (Mln) and adipic (Adp) acids were obtained {emoxypinium maleate, C₈H₁₂NO⁺·C₄H₃O₄⁻, [EMX+Mlt], emoxypinium malonate, C₈H₁₂NO⁺·C₃H₃O₄⁻, [EMX+Mln], and emoxypinium adipate, C₈H₁₂NO⁺·C₆H₉O₄⁻, [EMX+Adp]} and their crystal structures determined. The molecular packing in the three EMX salts was studied by means of solid‐state density functional theory (DFT), followed by QTAIMC (quantum theory of atoms in molecules and crystals) analysis. It was found that the major contribution to the packing energy comes from pyridine–carboxylate and hydroxy–carboxylate heterosynthons forming infinite one‐dimensional ribbons, with [EMX+Adp] additionally stabilized by hydrogen‐bonded C(9) chains of Adp⁻ ions. The melting processes of the [EMX+Mlt] (1:1), [EMX+Mln] (1:1) and [EMX+Adp] (1:1) salts were studied and the fusion enthalpy was found to increase with the increase of the calculated lattice energy. The dissolution process of the EMX salts in buffer (pH 7.4) was also studied. It was found that the formation of binary crystals of EMX with dicarboxylic acids increases the EMX solubility by more than 30 times compared to its pure form.